Cosentyx market seen growing to $8.74 million by 2030

The Business Research Company says the global Cosentyx drug market is expanding as autoimmune disease rates rise and biologic use widens. North America led the market in 2025, while Asia-Pacific is projected to grow fastest through 2030.

Why it matters: - Cosentyx is positioned as a key biologic for autoimmune diseases, so market growth points to broader demand for targeted treatments in psoriasis, psoriatic arthritis and related conditions. - The report’s forecast suggests the category will keep expanding as more patients are diagnosed and biologic access improves. - The full report is aimed at companies tracking market size, regional demand and competitive positioning.

What happened: - The Business Research Company published a report on the global Cosentyx drug market on November 2, 2026. - The report estimates the market will rise from $5.68 million in 2025 to $6.21 million in 2026. - The report projects the market will reach $8.74 million by 2030. - The report covers regions including Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

The details: - Cosentyx, or secukinumab, is a prescription biologic developed by Novartis. - Cosentyx is a monoclonal antibody that inhibits interleukin-17A, a protein involved in inflammatory response. - The drug is used for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis. - Cosentyx is administered by subcutaneous injection. - The report links prior market growth to approval of IL-17 inhibitors, high prevalence of psoriasis and arthritis, limited effectiveness of TNF inhibitors in some patients, adoption by specialist dermatologists and established biologic treatment guidelines. - The report says future growth will be supported by broader diagnosis of autoimmune diseases, more approved indications, rising patient awareness, improved biologic access and more long-term efficacy data. - The report highlights rising adoption of IL-17 inhibitor therapies, expanded use across autoimmune conditions, longer-term maintenance treatment and demand for self-administered injectable biologics as key trends. - North America held the largest market share in 2025. - Asia-Pacific is expected to grow fastest during the forecast period. - The report includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, and updated graphics and tables. - The report also offers a free sample download at the sample request page.

Between the lines: - The forecast reflects a shift from broad immunology adoption toward more targeted, long-term biologic care. - The regional split suggests mature demand in North America and faster expansion in markets where biologic access is still widening. - Rising healthcare spending and autoimmune prevalence are the key macro tailwinds behind the outlook.

What's next: - The report expects continued growth through 2030 as more patients enter diagnosis and treatment pathways. - Competitive focus is likely to stay on access, self-administration, and expansion into additional autoimmune indications. - The Business Research Company says updated report tools and forecasting dashboards are now part of the 2026 edition.